

CMIC HOLDINGS implements goBalto Activate to Accelerate Study Startup

CMIC HOLDINGS to further bolster the clinical study startup process
throughout Asia using cloud software

CMIC HOLDINGS is using goBalto's flagship product, Activate, for multi-country studies being conducted in Malaysia, Singapore, Taiwan, Philippines, Thailand, Japan, and South Korea. CMIC HOLDINGS is benefiting from Activate's robust library of country-specific workflows and management-based approach to site activation.

Activate allows CMIC HOLDINGS to track country and site milestones, streamlining the study startup process by ensuring clinical operations has real-time status updates, and ensuring efficiency gains by eliminating "hidden" communications created by relying on email and manual spreadsheets.

Kazuo Nakamura, Chairman & CEO, at CMIC HOLDINGS stated, "Activate allows us to minimize risk in starting clinical trials and ensure compliance. Activate's workflows standardize processes and guide our clinical operations teams to complete and track specific documents and tasks for any site, country, or study based on regulatory requirements and our company's standard operating procedures (SOPs)."

Peyni Chan, Managing Executive Director of CMIC Asia-Pacific, said "leveraging these established submission dossier packages and workflows in various countries will provide higher accuracy and completeness. Working on the same platform by different teams located in the region will make the work processes more efficient and effective, also helping us centrally manage the start-up activities."

"Activate allows the project management team at CMIC HOLDINGS to drive discussions and decision-making on bottlenecks impacting site activation. Significantly, time is not wasted charting data and compiling status updates, a practice that is typical with older methods, such as Excel," said Jae Chung, goBalto's founder and president. "The adoption of Activate at CMIC HOLDINGS further bolsters our international expansion and growth in the number of global clinical trials utilizing our industry first end-to-end study startup platform to accelerate clinical trials and speed therapies to patients in need."

【CMIC HOLDINGS Co., Ltd.】

CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for development, manufacturing, sales, and marketing of pharmaceutical industry. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model that we call "Pharmaceutical Value Creator (PVC)" based on our abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilize PVC to create new value in the healthcare field. For details, visit www.cmic-holdings.co.jp/e/.

Press contact:

CMIC HOLDINGS Co., Ltd.

Corporate Communication Division PR Group

Tel:+81-3-6779-8200 / E-mail: irpr@cmic.co.jp